DT is an investor and wants a return on his investment. He is not in this for an underpaid job. He has already said the best deal will most likely be done with high quality Phase 2 efficacy data and that most buyouts happen post Phase 2, when the drug has been de-risked in the eyes of big pharma. He has also stated that the highest return on equity for small biotechs is achieved after Phase 2 validation. Also he has made it clear that he doesn’t want to hang around any longer than he has to.
RAC Price at posting:
$1.39 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)